AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05432791 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05432791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT05432791 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT05432791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05432791 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05432791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05432791 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05432791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT05432791 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT05432791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT05432791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib
Description: Given PO
Study NCT05432791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT05432791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trabectedin
Description: Given IV
Study NCT05432791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transthoracic Echocardiography
Description: Undergo TTE
Study NCT05432791 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transthoracic Echocardiography
Description: Undergo TTE
Study NCT06309784 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drill Guidance System (DGS)
Description: During a standard surgical procedure where a drill/k wire is being inserted the surgeon may choose (in advance) to supplement their drilling with use of the Drill Guidance System. This will be a supplement to normal practice. it is anticipated it will make surgery more accurate, swifter and safer. If however the surgeon is not finding the DGS useful it can be abandoned and standard drilling with X-ray guidance used
Study NCT04708834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Troriluzole (BHV-4157)
Description: 200 mg daily first 2 weeks, 280 daily following first 2 weeks
Study NCT06210958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intertransverse process block
Description: The patients will be randomized into 2 groups which will receive the different techniques of the intertransverse process block
Study NCT05692180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab active solution will be administered SC to the patients.
Study NCT05692180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution will be administered SC to the patients.
Study NCT04859283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intranasal dexmedetomidine 1µg/kg will be administered 30min before the induction of anesthesia using a LMA MAD Nasal-device
Study NCT04859283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal saline (10 µL/kg) will be administered 30 min before the induction of anesthesia using a LMA MAD NasalTM -device. The dose is euvolemic to 1 µg/mL dexmedetomidine.
Study NCT06108596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab with Interleukin-2+CAPOX
Description: Sintilimab with Interleukin-2+CAPOX
Study NCT05534802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Description: On the basis of conventional treatment, according to the instructions or previous research doses (general anesthesia and tracheal intubation, after cardiopulmonary bypass transfer starts): 10,000 U/kg Ulinastatin (National Medicine Approval No. H19990134, Guangdong Tianpu Biochemical Pharmaceutical Co., Ltd. Co., Ltd., Guangzhou, China) was dissolved in 50 ml of normal saline for 1 hour and pumped through the central vein.
Study NCT05534802 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: saline
Description: On the basis of conventional treatment, 50 ml of normal saline for 1 hour and pumped through the central vein.
Study NCT05457738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-REVA® app
Description: Use of a smartphone app designed for home-based exercise therapy of patients with intermittent claudication. App's name is E-REVA®.
Study NCT05457738 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No E-REVA® app
Description: No use smartphone
Study NCT04867954 — intervention group
Intervention type: OTHER
Intervention: Ensure Plus®
Description: In-between two MRI exams, patients will ingest a standardized meal of two cans (16oz) of Ensure Plus® (Abbott Laboratories), providing a 700cal meal (13g protein, 11g fat, 50g carbohydrates), proven to elicit a strong hyperemic splanchnic response.
Study NCT04867954 — intervention group
Intervention type: OTHER
Intervention: Pre-clinical validation contrast enhanced MRI
Description: Participants will be asked to complete a single research visit that will include a contrast enhanced MRI scan lasting up to 1 hour. Participants will be asked to fast for at least 5 hours prior to the exam. Participants will be screened a final time for contraindications to contrast enhanced MR imaging; an IV will be placed; and participants will be positioned in the MR scanner, asked to lie as still as possible and to follow some breath hold instructions.
Study NCT05637281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indometacin
Description: Besides the conventional treatment, indomethacin will be given to the patients in the convention + indomethacin group.
Study NCT05637281 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: conventional treatment
Description: All enrolled patients received conventional management according to AP guidelines of International Association of Pancreatology and the Chinese Society of Gastroenterology, including goal-directed fluid resuscitation, oxygen supply even mechanical ventilation, and nutritional support if necessary.
Study NCT05637281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: All enrolled patients received conventional management according to AP guidelines of International Association of Pancreatology and the Chinese Society of Gastroenterology, including goal-directed fluid resuscitation, oxygen supply even mechanical ventilation, and nutritional support if necessary.
Study NCT05128409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XKH001 Injection
Description: 0.5mg/kg: 3Subjects,1Sentinel Participants 1.67mg/kg: 6Subjects, ,1Sentinel Participants 3.34mg/kg: 6Subjects,1Sentinel Participants 5.0mg/kg: 6Subjects, ,1Sentinel Participants 10.0mg/kg: 6Subjects,1Sentinel Participants
Study NCT05128409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XKH001Placebo Injection
Description: 1.67mg/kg: 2Subjects,1Sentinel Participants 3.34mg/kg: 2Subjects,1Sentinel Participants 5.0mg/kg: 2Subjects,1Sentinel Participants 10.0mg/kg: 2Subjects, 1Sentinel Participants
Study NCT04867954 — intervention group
Intervention type: OTHER
Intervention: Clinical validation MRI
Description: Participants will be screened for any previous reactions to Ferumoxytol or GBCAs and dosing will be consistent with standard of care.~Participants will then undergo a research MRI lasting approximately 1.5 hours.~* All participants will be positioned in the MRI scanner for the initial scanning session (30 min) during which a 1/2 or 3/4 of the full dose of gadolinium based contrast agent (GBCA) or the total dose of Ferumoxytol will be administered.~* The first 50 participants will be removed from the scanner bore, repositioned, and scanned for an additional 15 minutes (repeatability testing).~* All participants will then be removed from the scanner and asked to consume 16 ounces of Ensure Plus®. After 20 minutes, they will be repositioned in the scanner for an additional scanning session (15 minutes) during which, the remaining 1/4 or 1/2 dose of GBCA will be administered, if required.
Study NCT04867954 — intervention group
Intervention type: OTHER
Intervention: Pre-clinical validation contrast enhanced MRI + fasting
Description: Participants will be asked to complete a single research visit that will include a contrast enhanced MRI scan lasting up to 1.5 hours. Participants will be asked to fast for at least 5 hours prior to the exam. Participants will be screened a final time for contraindications to contrast enhanced MR imaging; an IV will be placed; and participants will be positioned in the MR scanner, asked to lie as still as possible and to follow some breath hold instructions.
Study NCT06116682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Given amivantamab-SC
Study NCT06116682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT06116682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT06116682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05419479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZIMBERELIMAB
Description: Via IV on two days per cycle, dosage per protocol
Study NCT05419479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOMVANALIMAB
Description: Via IV on two days per cycle, dosage per protocol
Study NCT05419479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: Via IV on two days per cycle, dosage per protocol
Study NCT05419479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: every two weeks through an infusion at a dose determined by physician
Study NCT06378138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-248
Description: Eligible patients will receive ICP-248 orally as per the protocol，once daily for every 28 days as one treatment cycle
Study NCT06378138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Eligible patients will receive Orelabrutinib orally as per the protocol，once daily for every 28 days as one treatment cycle
Study NCT04928846 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telisotuzumab Vedotin
Description: Intravenous (IV) Infusion
Study NCT04928846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: IV Infusion
Study NCT05069077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: In the music group, music that chosen by the participant will be played through a speaker by the nursing staff during outpatient hysteroscopy. Music will be played through a speaker instead of headphones in order to maintain good communication and interaction between the participant and the doctor.
Study NCT05069077 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No music
Description: Participants in the non-music group will undergo outpatient hysteroscopy in the same setting and standard procedure without listening to any music.
Study NCT05524454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel CBCT Imaging
Description: One or two CBCT images are acquired on the novel CBCT imaging system.
Study NCT05911633 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BioPearl™
Description: TACE
Study NCT05030155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: 300 mg/month subcutaneous
Study NCT05030155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cyclophosphamide/azathioprine
Description: Patients with FFS≥1 will receive cyclophosphamide then azathioprine
Study NCT05030155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with FFS=0 will receive placebo
Study NCT05030155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients with FFS=0 will receive placebo
Study NCT05123352 — intervention group
Intervention type: OTHER
Intervention: collection of biological samples and clinical data
Description: blood and feces samples
Study NCT06180135 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TURKISH COFFEE DRINK
Description: TURKISH COFFEE DRINK
Study NCT06180135 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FENNEL TEA DRINK
Description: FENNEL TEA DRINK
Study NCT06365125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eCHECKUP TO GO
Description: Single session, web-based intervention for college students aimed at increasing awareness of consequences related to heavy alcohol use and increase motivation to modify one's alcohol use.
Study NCT06365125 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eCHECKUP TO GO
Description: Single session, web-based intervention for college students aimed at increasing awareness of consequences related to heavy alcohol use and increase motivation to modify one's alcohol use.
Study NCT06365125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging boosters
Description: Text messages sent a few times per week following completion of eCHECKUP TO GO to reinforce concepts and assist with goal setting and goal attainment in everyday life
Study NCT05205304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D'Oxyva
Description: The transdermal CO2 was administered via non-invasive vaporization technique accommodated by deoxyhemoglobin vasodilator (D'Oxyva)
Study NCT05056129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensor-controlled digital game (SCDG)
Description: The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid rehospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal HF health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback (e.g., reduce fluid intake or call doctor for weight gain) to motivate engagement in and generate habit formation of heart failure related self-management behaviors.
Study NCT05056129 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sensor Only
Description: Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). This group will also be provided with standardized evidence-based HF educational material.However, the data from the Withings sensors will not be routed to the SCDG.
Study NCT04671667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT04671667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT04671667 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT04671667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT04671667 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT04671667 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04671667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04671667 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT04671667 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Proton Beam Radiation Therapy
Description: Undergo PBRT
Study NCT05137080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 24mg dexamethasone
Study NCT05137080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline
Description: Isotonic saline
Study NCT04929028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anoscopy
Description: Undergo anoscopy
Study NCT04929028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04929028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT04929028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Undergo colonoscopy
Study NCT04929028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or FDG PET/CT
Study NCT04929028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Rectal Examination
Description: Undergo digital rectal exam
Study NCT04929028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT06462729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LDGraft
Description: LDGraft 0.5mg/cc rhBMP-2 applied within intervertebral cage with placement of anterior fixation (plate and screws)
Study NCT06462729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LDGraft
Description: LDGraft 1.0mg/cc rhBMP-2 applied within intervertebral cage with placement of anterior fixation (plate and screws)
Study NCT06462729 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allograft Bone
Description: Allograft bone (100% human tissue product) applied within intervertebral cage with placement of anterior fixation (plate and screws)
Study NCT05812053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulpotomy
Description: Teeth will be anesthetized then Rubber dam and high suction will be used in pulpotomy procedure. Cavity outline was performed by sterile #330 high speed bur using water spray. Caries was removed by large spoon excavator. When pulpal exposure occurred, the roof of pulp chamber removed by low speed round bur. Haemostasis was obtained by applying pressure with moist cotton pellet with saline. Then the test materials was applied. after that, pulp stumps of all molars in each group will be dressed using Intermediate restorative material then the tooth will be restored with a preformed stainless steel crown
Study NCT05812053 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulpotomy
Description: Teeth will be anesthetized then Rubber dam and high suction will be used in pulpotomy procedure. Cavity outline was performed by sterile #330 high speed bur using water spray. Caries was removed by large spoon excavator. When pulpal exposure occurred, the roof of pulp chamber removed by low speed round bur. Haemostasis was obtained by applying pressure with moist cotton pellet with saline. Then the test materials was applied. after that, pulp stumps of all molars in each group will be dressed using Intermediate restorative material then the tooth will be restored with a preformed stainless steel crown
Study NCT05812053 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: cone beam computed tomography (CBCT) assessment
Description: a post-operative CBCT image will be taken immediately after completing the procedure with fixed exposure parameters (120 Kv, 5mA, and 0.125mm voxel size) using the smallest field of view (8D, 8Hcm) also, after 6 and 12 months follow-up periods.
Study NCT05812053 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: cone beam computed tomography (CBCT) assessment
Description: a post-operative CBCT image will be taken immediately after completing the procedure with fixed exposure parameters (120 Kv, 5mA, and 0.125mm voxel size) using the smallest field of view (8D, 8Hcm) also, after 6 and 12 months follow-up periods.
Study NCT05785039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion
Study NCT05341973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Self-Management Program will increase Self-Efficacy, Self-Care Management in Hypertension Patients.
Study NCT04929028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Receive FDG
Study NCT04929028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT04929028 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT04929028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Biopsy
Description: Undergo lymph node biopsy
Study NCT04929028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI or PET/MRI
Study NCT04929028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: Given IV
Study NCT04929028 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV